榮昌生物
醫(yī)學(xué)博士。從事腫瘤領(lǐng)域臨床研究近二十年,曾任職于解放軍總醫(yī)院第五醫(yī)學(xué)中心消化腫瘤科副主任,副主任醫(yī)師,碩士生導(dǎo)師。參與全球多中心臨床研究,國內(nèi)創(chuàng)新藥的早期、晚期臨床研究三十余項。曾作為信達(dá)生物醫(yī)學(xué)科學(xué)與戰(zhàn)略腫瘤部負(fù)責(zé)人,領(lǐng)導(dǎo)了信迪利單抗、佩米替尼在消化腫瘤多個適應(yīng)癥的成功獲批,以及多個早期分子在中國和海外的臨床開發(fā)。在BMJ, Lancet Oncology, Science Advance,Clinical Cancer Research等知名期刊發(fā)表學(xué)術(shù)論文二十余篇。目前負(fù)責(zé)榮昌生物腫瘤產(chǎn)品的全球臨床開發(fā)。
Senior Medical Oncologist with 20 years’ experiences in clinical studies, worked as deputy director of the GI Cancer Department of the Fifth Medical Center of PLA General Hospital. Successfully led the development of Sintilimab (anti-PD-1 antibody, Innovent) in GI cancer, got BLA approval for 1L HCC, 1L ESCC and 1L GC, Pemigetinib approval in greater China as global first FGFR inhibitor. Led early-stage and late-stage development of more than 20 oncology assets covering mAb, BsAb, small molecule and ADC. Published more than 20 peer-reviewed papers in BMJ, Lancet Oncology, Science Advance, Clinical Cancer Research, etc. Responsible for the global development strategy and implementation of Remegen oncology pipeline.?